Abstract
Medication-refractory focal epilepsy poses a significant challenge, with approximately 30% of patients ineligible for surgery due to the involvement of eloquent cortex in the epileptogenic network. For such patients with limited surgical options, electrical neuromodulation represents a promising alternative therapy. In this study, we investigate the potential of non-invasive temporal interference (TI) electrical stimulation to reduce epileptic biomarkers in patients with epilepsy by comparing intracerebral recordings obtained before, during, and after TI stimulation, and to those recorded during low and high kHz frequency (HF) sham stimulation. Thirteen patients with symptoms of mesiotemporal epilepsy (MTLE) and implanted with stereoelectroencephalography (sEEG) depth electrodes received TI stimulation with an amplitude modulation (AM) frequency of 130Hz (Δf), where the AM was delivered with lower frequency kHz carriers (1kHz + 1.13kHz), or higher frequency carriers (9kHz + 9.13kHz), targeting the hippocampus – a common epileptic focus and consequently stimulation target in MTLE.
Our results show that TI stimulation yields a statistically significant decrease in interictal epileptiform discharges (IEDs) and pathological high-frequency oscillations (HFOs) – specifically Fast-ripples (FR) –, where the suppression is apparent in the hippocampal focus and propagation from the focus is reduced brain-wide. HF sham stimulation at 1kHz frequency also impacted the IED rate in the cortex, but without reaching the hippocampal focus. The HF sham effect diminished with increasing frequencies (2, 5, and 9kHz, respectively), specifically as a function of depth into the cortex. This depth dependence was not observed with the TI, independent of the employed carrier frequency (low or high kHz). Our findings underscore the possible application of TI in epilepsy, as an additional non-invasive brain stimulation tool, potentially offering opportunities to assess brain region responses to electrical neuromodulation before committing to a deep brain stimulation (DBS) or responsive neurostimulation (RNS) implant. Our results further demonstrate distinct biophysical differences between kHz and focal AM stimulation.
Competing Interest Statement
N.K. and E.N. are shareholders of TI Solutions AG, a company dedicated to producing temporal interference (TI) stimulation devices to support TI research.
Clinical Trial
NCT06716866
Funding Statement
A.W. received funding from the European Union s Horizon Europe research and innovation programme under grant agreement No. 101101040 (TREATMENT) and No. 101088623 (EMUNITI). Effort on this project for both Drs. Daniel Drane and Emma Acerbo were in part supported by grants received from the National institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Healthy (NIH) [R01NS088748]. Emma Acerbo was also supported through the Emory Neuromodulation Technology Innovation Center (ENTICe).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Emory IRB of Emory University, Atlanta, GA, USA gave ethical approval for this work under the number IRB00099109. The ethical committee of St. Anne's University Hospital Brno, Brno, Czech Republic gave ethical approval for this work under the number IIT/2023/25. The ethical committee of the Institute of Neurosurgery and Neurointervention, Semmelweis University, Budapest, Hungary gave ethical approval for this work under the number OGYEI/56526-2/2023. All experiments were conducted after a clinical trial registration and agreement (NCT06716866).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All data produced in the present study are available upon request to the authors.
